Welcome to our dedicated page for Spruce Biosciences news (Ticker: SPRB), a resource for investors and traders seeking the latest updates and insights on Spruce Biosciences stock.
Spruce Biosciences reports developments as a late-stage biopharmaceutical company focused on novel therapies for neurological disorders with significant unmet medical need. Its recurring news centers on tralesinidase alfa enzyme replacement therapy, or TA-ERT, for Sanfilippo Syndrome Type B (MPS IIIB), including clinical data presentations, FDA interactions and regulatory planning for the program.
Company updates also cover financial results, capital actions involving common stock and pre-funded warrants, investor conference participation, and additions to commercial leadership as Spruce builds capabilities around a potential rare-disease launch.
Spruce Biosciences (Nasdaq: SPRB) reported full-year 2025 results and corporate updates on March 9, 2026. Key items: the company completed positive Type B FDA meetings, anticipates a BLA submission for TA-ERT in Q4 2026, appointed a chief commercial officer, and secured a loan facility up to $50.0 million with $15.0 million funded.
Financials: cash and equivalents were $48.9M at year-end, R&D expenses declined to $19.5M, total operating expenses were $36.5M, and net loss was $39.0M for 2025.
Spruce Biosciences (Nasdaq: SPRB) appointed Dale Hooks as Chief Commercial Officer on March 9, 2026. Mr. Hooks brings nearly 35 years of commercial experience and leadership on 21 new product launches. Spruce said he will support preparation for a planned BLA submission for tralesinidase alfa (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB). The company granted Mr. Hooks 11,000 restricted stock units as an inducement award, subject to four-year time-based vesting in equal annual installments.
Spruce Biosciences (Nasdaq: SPRB) said CEO Javier Szwarcberg will present at two investor conferences in Miami in March 2026: the Leerink Global Healthcare Conference on March 9, 2026 at 11:20 a.m. ET and The Citizens Life Sciences Conference on March 10, 2026 at 12:30 p.m. ET.
Both presentations will be fireside chats with 1x1 meetings; live webcasts will be available on the company website and archived for approximately 90 days.
Spruce Biosciences (Nasdaq: SPRB) completed two Type B meetings with the U.S. FDA and will pursue a BLA for tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo syndrome type B (MPS IIIB).
The FDA indicated CSF HS-NRE could serve as a reasonably likely surrogate endpoint for accelerated approval and requires one DP PPQ batch at submission plus a second DP PPQ batch before midcycle review, shifting the anticipated BLA submission to Q4 2026.
Spruce Biosciences (Nasdaq: SPRB) said CEO Javier Szwarcberg will join a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 at 3:20 p.m. ET. The session will be webcast live, with an archived replay available on the company's events page for about 90 days.
Spruce Biosciences (Nasdaq: SPRB) reported long-term data showing weekly tralesinidase alfa enzyme replacement therapy (TA-ERT) normalized CSF HS-NRE and stabilized cognitive, communication, and motor outcomes over up to six years versus untreated natural history patients. Approximately 6,000 doses were administered to 22 patients with a safety profile consistent with intracerebroventricular administration. A sibling case comparison showed higher functioning in a treated sibling versus an untreated sibling at similar ages. The company said it will pursue a biologics license application and potential U.S. FDA approval.
Spruce Biosciences (Nasdaq: SPRB) appointed Daven Mody, Pharm.D., as Senior Vice President, Regulatory and Quality, and Bruno Gagnon, B.Pharm., M.Sc., as Senior Vice President, Clinical Development Operations, effective February 2, 2026.
The hires bring regulatory and rare‑disease clinical operations experience to support a planned BLA submission and a confirmatory study for tralesinidase alfa (TA‑ERT) in Sanfilippo Syndrome Type B (MPS IIIB). Each executive received inducement restricted stock units for 5,500 shares vesting equally over four years, approved under Nasdaq Listing Rule 5635(c)(4).
Spruce Biosciences (Nasdaq: SPRB) will present long‑term clinical data for tralesinidase alfa enzyme replacement therapy (TA‑ERT) at WORLDSymposium Feb 2–6, 2026 in San Diego.
Presentations on Feb 5, 2026 detail a profound, durable reduction of heparan sulfate (HS), stabilization of cognitive function and cortical gray matter volume, and a sibling comparison showing divergent neurocognitive outcomes with and without TA‑ERT.
Harbour BioMed exercised a warrant to acquire common stock in Spruce Biosciences (Nasdaq: SPRB), resulting in Harbour BioMed holding approximately 3.8% of Spruce's outstanding shares and approximately 3.1% of Spruce's fully diluted shares as of Sept 30, 2025. The warrant was issued in connection with a license and collaboration between HBM Alpha Therapeutics and Spruce to advance SPR202, an anti‑corticotropin‑releasing hormone monoclonal antibody for disorders including congenital adrenal hyperplasia. Harbour BioMed framed the exercise as a move to deepen a strategic partnership beyond a licensor‑licensee relationship to align development incentives.
Spruce Biosciences (Nasdaq: SPRB) entered a loan facility with Avenue Capital for up to $50 million, including an initial funded tranche of $15 million expected around January 9, 2026. The 42-month facility has three additional tranches totaling up to $35 million that are contingent on achievement of regulatory and commercial milestones tied to the planned BLA filing and potential launch of tralesinidase alfa enzyme replacement therapy (TA-ERT) for MPS IIIB. Spruce reported preliminary cash and cash equivalents of $48.9 million as of December 31, 2025 and expects the initial draw to extend its cash runway into 2027 while accelerating pre-launch commercial activities.